Ontology highlight
ABSTRACT:
SUBMITTER: Siegel DS
PROVIDER: S-EPMC4123387 | biostudies-literature | 2012 Oct
REPOSITORIES: biostudies-literature
Siegel David S DS Martin Thomas T Wang Michael M Vij Ravi R Jakubowiak Andrzej J AJ Lonial Sagar S Trudel Suzanne S Kukreti Vishal V Bahlis Nizar N Alsina Melissa M Chanan-Khan Asher A Buadi Francis F Reu Frederic J FJ Somlo George G Zonder Jeffrey J Song Kevin K Stewart A Keith AK Stadtmauer Edward E Kunkel Lori L Wear Sandra S Wong Alvin F AF Orlowski Robert Z RZ Jagannath Sundar S
Blood 20120725 14
Carfilzomib is a next-generation, selective proteasome inhibitor being evaluated for the treatment of relapsed and refractory multiple myeloma. In this open-label, single-arm phase 2 study (PX-171-003-A1), patients received single-agent carfilzomib 20 mg/m(2) intravenously twice weekly for 3 of 4 weeks in cycle 1, then 27 mg/m(2) for ≤ 12 cycles. The primary endpoint was overall response rate (≥ partial response). Secondary endpoints included clinical benefit response rate (≥ minimal response), ...[more]